Eder, Lihi
Tony, Hans-Peter
Odhav, Satish
Agirregoikoa, Eva Galindez
Korkosz, Mariusz
Schwartzman, Sergio
Sprabery, Aubrey Trevelin
Gellett, Amanda M.
Park, So Young
Bertram, Clinton C.
Ogdie, Alexis
Article History
Received: 21 January 2022
Accepted: 15 March 2022
First Online: 9 April 2022
Declarations
:
: The studies and the Rapid Service Fee were sponsored by Eli Lilly and Company.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: Lihi Eder contributed to the conception of the work, design of the work, interpretation of data for the work, and critical revision of the manuscript for important intellectual content. Hans-Peter Tony contributed to the acquisition of data for the work, interpretation of data for the work, and critical revision of the manuscript for important intellectual content. Satish Odhav, Trev Sprabery, Amanda Gellett, Clint Bertram, and Alexis Ogdie contributed to the interpretation of data for the work and critical revision of the manuscript for important intellectual content. Eva Galindez Agirregoikoa contributed to the analysis of data for the work, interpretation of data for the work, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. Marius Korkosz contributed to the acquisition of data of the work and critical revision of the manuscript for important intellectual content. Sergio Schwartzman contributed to the analysis of data for the work, interpretation of data for the work, and critical revision of the manuscript for important intellectual content. So Young Park contributed to the analysis of data for the work, interpretation of data for the work, and drafting of the manuscript
: The authors would like to thank Nicole Lipitz of Syneos Health for medical writing support, funded by Eli Lilly and Company.
: Lihi Eder has received unrestricted educational and research grants and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sandoz, and UCB. Hans-Peter Tony has received payments from Eli Lilly and Company. Satish Odhav and/or his institution has received research grants and speaking or consulting fees from Abbvie, Amgen, Astra Zeneca, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Exagen, Galapagos (Gilead), GSK, Horizon, Ironwood, Janssen, Mallinckrodt, Nektar, Nichi-Iko, Novartis, Pfizer, Primus, Regeneron, Sanofi, Selecta, and UCB. Eva Galindez Agirregoikoa and Mariusz Korkosz have no payments to disclose. Sergio Schwartzman has received speaking fees from Abbvie, Genentech, Janssen, Eli Lilly and Company, Novartis, Pfizer, Regeneron, Sanofi, UCB; has stock ownership for Amgen, Boston Scientific, Gilead, Medtronic, and Pfizer; has received consulting fees from Abbvie, Crescendo, Dermtech, Janssen, Gilead, Lilly, Myriad, Novartis, Regeneron, Samsung, Sanofi, and UCB; serves as a board member of the National Psoriasis Foundation; and serves on the scientific advisory board for Myriad. Aubrey Trevelin Sprabery, Amanda M Gellett, Chen-Yen Lin, So Young Park, and Clinton C Bertram report employment with and stock ownership for Eli Lilly and Company. At the time of this publication, Amanda M Gellett is now affiliated with Sanofi Genzyme. Alexis Ogdie and/or her institution has received grants from Amgen, Novartis, and Pfizer; has received consulting fees from Abbvie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Pfizer, and Novartis; has received speaking fees from Abbvie, Amgen, and Celgene; and has received royalties from Novartis.
: The SPIRIT-P1 and SPIRIT-P2 trials were conducted in accordance with the ethical principles of the Declaration of Helsinki as well as local laws and regulations. All trial participants provided written informed consent. Protocols and consent forms were approved by the institutional review board or ethics committee of each site, including the Western Institutional Review Board (SPIRIT-P1) and the Bellberry Human Research Ethics Committee (SPIRIT-P2). A listing of individual sites for the trials are included in the supplements of the primary manuscripts [CitationRef removed, CitationRef removed]. Both trials were registered on ClinicalTrials.gov (SPIRIT-P1: NCT01695239, SPIRIT-P2: NCT02349295).
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: An overview of preliminary results on PsA patient subgroups related to this post-hoc analysis was presented at the 2019 Annual Scientific Congress of the European League Against Rheumatism (EULAR) from June 12 through 15 in Madrid, Spain.